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Neonatal Respiratory Distress 
Syndrome: Things to Consider and 
Ways to Manage
Bita Najafian and Mohammad Hossein Khosravi
Abstract
Involving more commonly the premature (less than 37 weeks of gestational 
age) infants, neonatal respiratory distress syndrome is an important clinical 
syndrome responsible for a high rate of mortality and morbidity. The main 
progress in respiratory distress syndrome (RDS) management is attributable 
to prescription of surfactant for fastening pulmonary maturation. Respiratory 
protection, such as mechanical ventilation and nasal continuous positive airway 
pressure, and surfactant are building blocks of disease treatment. In this chap-
ter, we are going to have a rapid review on epidemiology, diagnosis and treat-
ments of RDS.
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1. Introduction
Involving more commonly the premature (less than 37 weeks of gestational age) 
infants, neonatal respiratory distress syndrome (NRDS), is an important clinical 
syndrome responsible for a high rate of mortality and morbidity. Reports have 
shown that about 12% of infants are preterm in the United States, while the preva-
lence ranges between 6 and 11% in European countries [1, 2]. NRDS is a leading 
cause of admission to neonatal intensive care unit (NICU) with estimated incidence 
rate of 7.8% and mortality rate of 50% in premature infants [3–5]. The severity usu-
ally increases during the first 48 hours of birth [6]. The prevalence and the severity 
of NRDS decrease as the gestational age increases [7–9].
A variety of factors including cesarean section, prematurity, maternal diabetes 
and genetic variations have been reported to play role in pathogenesis of NRDS 
[10, 11]. Damage to type II alveolar cells is another considered mechanism for 
NRDS. Diffuse alveolar capillary injury results in progressive increased perme-
ability as well as pulmonary and alveolar edema, which make the type II alveolar 
cells nonfunctional. All these processes lead into severe hypoxemia due to abnormal 
ventilation/perfusion ratio [12, 13].
NRDS is a result of pulmonary immaturity mostly caused by insufficient levels 
of surfactant [14, 15]. The condition is developed through hypoventilation, hypox-
emia and respiratory acidosis [14, 15].
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2. Diagnosis
Early diagnosis is of a high importance due to available management methods 
[15, 16]. A combination of clinical signs and different modalities such as chest 
radiographies and laboratory tests are needed for diagnosing NRDS [14].
2.1 Clinical signs and symptoms
There are a wide range of clinical signs from nasal flaring and cyanosis to 
substernal and intercostal retraction, tachypnea and grunting [16]. A risk assess-
ment tool called “Clinical Risk Index for Babies” (CRIB) is used to estimate the need 
for admission of infants in NICU [17]. Different factors such as gestational age, 
birth weight and base excess during the first 12 hours of life, fraction of inspired 
oxygen and presence of congenital malformations are considered in this assessment 
(Table 1).
2.2 Laboratory tests
Arterial oxygen pressure (PaO2) is a marker for diagnosis of NRDS. PaO2 less 
than 50 mmHg with cyanosis in room air or need for supplementary oxygen for 
maintaining O2 level above 50 mmHg are indicators for NRDS [14]. Metabolic and 
respiratory acidosis are measured through a blood sample.
Gastric aspirate shake test (GAST) is another laboratory measure with reported 
sensitivity of 100% and specificity of 92% for diagnosis of NRDS [18]. GAST 
identifies presence or lack of surfactant in the gastric fluid aspirates [19].
Recently published studies have mentioned a new factor for early detection and 
prediction of NRDS in premature infants. Transforming growth factor β1 (TGF-β1) 
is a cytokine, which has the responsibility for regulating and differentiating differ-
ent cell lines [20, 21]. These studies have marked the role of TGF-β1 in development 
of various acute and chronic lung injuries and concluded that this factor can be 
used as a diagnostic and prognostic one [22]. The same role has been considered for 
interleukin-6, which is a glycoprotein secreted mostly from T cells and mononuclear 
macrophages causing inflammatory reactions [23, 24].
2.3 Chest radiographs
Previous studies have reported a remarkable diagnostic value for chest radio-
graphs [25]. Features such as reduced lung expansions, air bronchograms and 
dilated bronchioles can be seen in NRDS [15]. In addition to diagnostic use, chest 
radiographs have another application to confirm endotracheal tube position. 
Premature infants receive continuous positive airways pressure (CPAP) for aug-
menting oxygenation in addition to simplifying intra-tracheal administration of 
surfactants [14]. The precise adverse effects of radiation have not been yet deter-
mined; however, some efforts are being done to find an alternative method for chest 
radiography [26–28].
2.4 Ultrasound
Previously, lung ultrasound (LUS) was not used for infant chest imaging due 
to interference of air levels. This modality has its own potential adverse effects 
including thermal and mechanical tissue damage [27, 29]. Recently, lung ultrasound 
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has been widely used as an accurate diagnostic tool according to published clinical 
studies [4, 7, 16, 30–34]. Lack of normal air-filled levels and presence of fluid level 
is a diagnostic clue for NRDS.
A meta-analysis of six studies comparing LUS to chest x-ray for diagnosing 
NRDS reported a high diagnostic sensitivity (97%) and specificity (91%) for LUS 
[35]. They have also reported that transthoracic technique is superior to transab-
dominal approach for diagnosing NRDS.
On the other hand, some researchers believe that lung ultrasound can be helpful 
only as a complementary diagnostic tool rather than a diagnostic method [36]. They 
have mentioned in a letter-to-editor that only chest radiographs and CT scan can be 
reliable for diagnosing neonatal respiratory distress syndrome.
Factor Score
Birth weight (gr)
>1350 0
851–1350 1
701–850 4
≤700 7
Gestation (week)
>24 0
≤24 1
Congenital malformations*
None 0
Not actually life-threatening 1
Actually life threatening 3
Maximum base excess in first 12 h (nmol/L)
>−7 0
−7 to −9.9 1
−10 to 14.9 2
≤−15 3
Minimum appropriate FIO2 in first 12 h
≤40% 0
41–60% 2
61–90% 3
91–100% 4
Maximum appropriate FIO2 in first 12 h
<40% 0
41–80% 1
81–90% 3
91–100% 5
*Excluding inevitably lethal malformations.
Table 1. 
CRIB score.
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3. Management
3.1 Mechanical ventilation
Mechanical ventilation is the most commonly applied treatment method for 
NRDS in clinical practice [37–39]; although mechanical ventilation and continu-
ous oxygen therapy are independent risk factors for development of NRDS to 
bronchopulmonary dysplasia (BPD) [40, 41]. Noninvasive respiratory support 
methods such as nasal intermittent positive pressure ventilation (NIPPV), high 
flow nasal cannula (HFNC) and nasal continuous positive airway pressure 
(NCPAP) are being used more commonly as the initial ways of management, 
which may decrease need for intubation in up to 50% of infants [42–44]. On 
the other hand, the failure of noninvasive respiratory support results in delayed 
administration of surfactant and prolonged mechanical ventilation. Also, this may 
be associated with higher incidence of bronchopulmonary dysplasia (BPD), major 
morbidity or even death [45, 46]. So, it seems that a combination of early respira-
tory support and prescription of surfactant may improve the treatment results. 
Administration of surfactant during NCPAP, less-invasive (LISA) and minimal-
invasive  surfactant administration (MISA) have shown convenient results in 
management of NRDS [47].
Recently published studies have introduced the aerosolized surfactant as a safe 
and efficient method of drug delivery [47]. It has been claimed that vibrating and 
ultrasonic mesh nebulizers have the ability to make surfactant aerosols without 
interfering with biochemical composition of medication [48–50]. It has been 
reported that aerosolized surfactant can be delivered using nasal cannula in nonin-
vasive respiratory support [51–55].
3.2 Surfactant
Pathophysiology of NRDS (inadequate production of pulmonary surfactant in 
premature infants) was first discovered by Avery and Mead in 1959, which resulted 
in changing the former name of the disease “hyaline membrane disease” [56]. This 
was a window to surfactant replacement therapy.
Lung surfactant is a mixture of phospholipids and some specific proteins 
secreted by epithelium of alveoli, which lines the small airways. It primarily 
reduces the surface tension of liquid presented in terminal air spaces [57]. Lack of 
pulmonary surfactant is the main result of NRDS; so, prescription of pulmonary 
surfactant can augment respiratory function and pulmonary compliance resulting 
in elevated oxyhemoglobin level [58–61]. Lack of surfactant results in a chain of 
problems from collapsed lung, tissue damage, reduced oxygenation and impaired 
function of alveolar epithelium, resulting in altered production of surfactant 
[62]. Fujiwara et al. reported the very first application of surfactant-TA in preterm 
infants with respiratory distress syndrome in 1980 [63].
There are different kinds of animal-derived as well as first- and second-genera-
tion synthetic surfactants [64]. As a natural surfactant, Curosurf is taken from pig 
lung, which is consisted of 41–48% lecithin and 51–58% of hydrophobin and other 
phospholipids. Liquid gel layer has the responsibility to absorb the Curosurf after 
its administration to the lungs [65]. Also, this medication has some adverse effects 
including respiratory discomforts and bucking [66, 67]. Administration of surfac-
tant involves frequent endotracheal intubation (INSURE: INtubation-SURfactant-
Extubation) and mechanical ventilation, which is associated with inevitable 
comorbidities [68, 69].
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Recently, in addition to the common INSURE method, a new method has come 
up and is getting more popular. This method is called a less-invasive surfactant 
administration (LISA), which has been reported to be more effective in prevention 
of bronchopulmonary dysplasia and reducing preterm infants’ mortality. In this 
method, surfactant is delivered through a thin catheter while the infant is under 
continuous positive airway pressure (CPAP) treatment. However, more large-scale 
randomized clinical trials are needed to make this method accepted as a routine in 
clinical practice [70].
3.3 Ambroxol hydrochloride
As an active metabolite of bromhexine, ambrotherxol or ambroxol hydrochlo-
ride has a mucolytic activity. A wide range of advantages have been reported for 
ambroxol hydrochloride from reducing production of hydrogen peroxide, stimulat-
ing secretion of pulmonary surfactant, reducing lung damage and alleviating the 
inflammatory response to relieving pulmonary edema and interstitial exudation. As 
a low-cost and high-efficacy medication, ambroxol hydrochloride is being used in 
clinical treatment of NRDS [71, 72]. There are reports about satisfactory results of 
combination of high-dose ambroxol hydrochloride and surfactant [37].
3.3.1 Nitric oxide (NO)
About 2% of all live births are involved with respiratory failure, which is 
responsible for more than one-third of neonatal mortalities [73]. Inhaled NO (iNO) 
reduces pulmonary vascular resistance, edema, lung inflammation and hypoxia, 
which makes the respiratory difficulties easier for infants [74]. Previous researches 
have also shown that iNO improves pulmonary angiogenesis and protects pulmo-
nary system against infections with no remarkable adverse effects on growth or 
neurodevelopmental status [75].
Neonatal respiratory distress syndrome (NRDS), as a result of inadequate 
surfactant production, leads to atelectasis and ventilation-perfusion (V/Q ) mis-
matching. Beside notable response to exogenous surfactant, it has been reported 
that iNO transiently improves oxygenation in infants with NRDS. Previous studies 
have shown that iNO therapy alone reduces mortality rate in preterm infants [76]. 
iNO improves V/Q matching, selectively dilates the pulmonary vasculature and 
decreases pulmonary inflammatory response. The most convenient advantage 
of iNO is reducing incidence of chronic lung disease in premature infants with 
RDS [77]. In other researches, premature infants with suboptimal response to 
exogenous surfactant showed beneficial clinical responses to combination therapy 
with iNO [78].
4. Prognosis
Neonatal respiratory distress syndrome is one of the major causes of premature 
death; however, a notable part of the survivors may develop bronchopulmonary 
dysplasia and suffer from chronic pulmonary diseases [67]. Prognosis of RDS is 
highly related to the treatment and management methods, which have been being 
developed since their discovery. The efficacy of each method for prognosis is 
under investigation. Also, gestational age has an important role in determining the 
prognosis, where late preterm infants usually have a better prognosis in comparison 
with early preterm infants.
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5. Conclusion
According to high prevalence and clinical importance of NRDS, seeking new 
methods of diagnosis and treatment is of a high importance. Available knowledge 
approves efficacy of surfactant as the stumbling block of medical NRDS manage-
ment; however, various methods of drug delivery are under development. It seems 
that a combination of respiratory support and surfactant is the ideal method of 
management.
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